WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 1 fonti

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

Raccontata da

morningstar.com

Timeline cronologica

lunedì 1 giugno 2026·morningstar.com
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand…
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema